Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
SNAP-8 is the trade-style name for acetyl octapeptide-3, an eight-residue synthetic peptide designed in cosmetic science as a longer analog of the hexapeptide acetyl hexapeptide-3 (Argireline). This article explains where the sequence comes from, what the SNARE-complex hypothesis behind it actually says, which parts of the evidence are in vitro and which are formulation studies, and why cosmetic-grade and research-grade material are documented differently.
What SNAP-8 is: sequence, mass and identifiers
Acetyl octapeptide-3 is the N-acetylated, C-amidated peptide Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, with PubChem CID 76283482, CAS 868844-74-0, formula C41H70N16O16S and a molecular weight of 1,075.2. PubChem lists SNAP-8, acetyl glutamyl heptapeptide-3 and acetyl octapeptide-1 among its synonyms, which is worth knowing because INCI-style names for cosmetic peptides are assigned by a numbering convention that does not describe the sequence, and more than one such name has been attached to this molecule.
The sequence is an extension of Argireline, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, by two residues (alanine and aspartate) at the C-terminus. Both peptides were designed by Lipotec, whose 1999-priority European patent application EP1180524 claims peptides of 3 to 30 adjacent residues taken from the amino-terminal end of the protein SNAP-25, and the hexapeptide is one of its named sequences. The single methionine at position three is the main chemical liability of the molecule: it can oxidize to methionine sulfoxide in solution or in a poorly stored powder, which adds 16 Da and shows up as an early-eluting shoulder on a reverse-phase chromatogram. A certificate for this peptide should therefore report the observed mass at or near 1,075 and show the main peak resolved from any plus-16 species.
The biology the design borrows: SNAP-25 and the SNARE complex
SNAP-25 is a 25 kDa protein of the presynaptic membrane that, together with syntaxin and the vesicle protein synaptobrevin (VAMP), forms the ternary SNARE complex that drives calcium-dependent vesicle fusion. Hodel's 1998 review in the International Journal of Biochemistry and Cell Biology summarizes its two helical domains and its role in docking and fusion. The complex is the target of botulinum neurotoxin type A: Blasi and colleagues showed in a 1993 Nature paper that the toxin's light chain is a zinc-dependent protease that selectively cleaves SNAP-25 near its C-terminus, which blocks transmitter release from synaptosomes.
The relevance of the N-terminus, which is where the SNAP-8 sequence comes from, was established in cell-free and cell-culture work. Fasshauer and Margittai reported in a 2004 Journal of Biological Chemistry study using fluorescence and circular dichroism spectroscopy that SNARE assembly begins with a slow, rate-limiting interaction between syntaxin and SNAP-25, and that N-terminal truncations of SNAP-25 prevented formation of the ternary complex. Yang, Xia and Liu had shown in 2000, in cultured rat cerebellar granule cells, that a SNAP-25 deletion mutant lacking C-terminal residues inhibited core-complex formation and glutamate release, and that an additional N-terminal 1-31 deletion abolished that inhibitory activity. Those results support the idea that the N-terminal helix of SNAP-25 is a site where a competing peptide could, in principle, interfere with assembly. They do not test any synthetic octapeptide.
The SNARE-mimic hypothesis and what tests it
The hypothesis is that a short peptide copying the N-terminal sequence of SNAP-25 competes with the native protein for its position in the forming SNARE complex, destabilizing the complex and reducing exocytosis. The primary published test of this idea is for the hexapeptide, not the octapeptide. Blanes-Mira and colleagues, in a 2002 International Journal of Cosmetic Science paper from Lipotec, reported that Argireline inhibited neurotransmitter release in an in vitro assay with a potency they described as similar to botulinum toxin A but with much lower efficacy, and attributed the effect to interference with formation or stability of the SNARE complex. The Lipotec patent describes the supporting assays as catecholamine release from chromaffin cells and an ELISA-based SNARE reconstitution test, with the hexapeptide blocking about 20 percent of release at 1 mM.
For SNAP-8 itself, the public record is thinner. Lubrizol, which now owns the Lipotec line, markets SNAP-8 peptide solution as an octapeptide analog positioned relative to the hexapeptide; the mechanistic description on the supplier side is that the sequence is analogous to the N-terminal of SNAP-25 and competes with the native protein for a position in the SNARE complex. Peer-reviewed mechanistic data specific to the octapeptide, such as a binding constant to syntaxin or a concentration-response curve in a reconstituted SNARE assay, are not something this review could locate in PubMed. The honest summary is that the mechanism is inferred from the hexapeptide's in vitro work and from SNAP-25 biology, and has not been independently characterized for the eight-residue version in the primary literature.
| Evidence layer | Model | What it shows | Applies to SNAP-8 directly? |
|---|---|---|---|
| SNAP-25 N-terminus is required for SNARE assembly | Purified proteins (spectroscopy); rat neuron culture | N-terminal truncations block ternary complex formation | No; native protein studies |
| Hexapeptide interferes with SNARE-dependent release | In vitro release assays (Lipotec) | Partial inhibition at high micromolar to millimolar concentration | No; hexapeptide analog |
| Octapeptide in cosmetic formulations | Supplier formulation data; topical studies of finished products | Product-level observations, not mechanism | Yes, but not mechanistic |
What is in vitro, what is formulation science, and what is not established
Every mechanistic claim for this peptide family rests on in vitro assays: cell-free SNARE reconstitution, chromaffin or neuronal cell release assays, and spectroscopy on purified SNARE proteins. The cosmetic literature that followed consists mostly of formulation and topical-application studies of finished products, which the 2017 review by Pai, Bhandari and Shukla in the Indian Journal of Dermatology, Venereology and Leprology groups under "neurotransmitter-affecting peptides" alongside signal and carrier peptides. Those studies evaluate a product, often a multi-ingredient emulsion, and cannot isolate the contribution of the peptide or confirm the mechanism. Related skin-penetration work on the hexapeptide by Kraeling and colleagues in 2015, using in vitro human skin, found very limited penetration from a cosmetic formulation, which is itself a reason to be cautious about reading a product-level observation as evidence of a SNARE-level effect.
What is not established, for either peptide, is any independently replicated measurement of SNARE-complex disruption at concentrations relevant to a formulation, any receptor or binding-site identity beyond the generic "competes with SNAP-25" model, and any data in laboratory animals that bears on mechanism. Neither acetyl octapeptide-3 nor acetyl hexapeptide-3 is an approved drug anywhere. The Cosmetic Ingredient Review Expert Panel's 2025 assessment in the International Journal of Toxicology covers the hexapeptide amide as a cosmetic ingredient at the low concentrations used in finished products; no equivalent CIR assessment of the octapeptide was located.
Cosmetic-grade versus research-grade material
The same sequence is sold into two different supply chains with different documentation, and this difference matters more than the name. Cosmetic-grade acetyl octapeptide-3 is typically supplied as a dilute aqueous solution for formulators; the Lubrizol product, for example, is listed under the INCI composition aqua, acetyl octapeptide-3 and caprylyl glycol, which means it is a preserved solution at a fraction of a percent peptide, specified for use in an emulsion. Its documentation is a cosmetic ingredient data sheet: INCI name, recommended use level, preservative system, microbial limits and shelf life. It is not meant to tell a laboratory the peptide's purity by area percent, its net peptide content, or its endotoxin load, because none of those matter for a leave-on cream.
Research-grade material is the lyophilized peptide itself, specified for in vitro work. The documentation that distinguishes it is the lot-matched certificate: identity by mass spectrometry against the expected 1,075.2 Da, purity by HPLC with the methionine-sulfoxide species resolved, net peptide content so the counter-ion and water fraction is known, and the endotoxin, sterility and heavy-metal lines that cell-based assays require. US Prime's SNAP-8 10 mg listing posts that certificate before purchase. A lab that needs a defined concentration of the pure peptide for a SNARE reconstitution or release assay cannot get there from a cosmetic solution of unknown exact strength, and a formulator does not need a certificate of net peptide content. The guides to reading a certificate of analysis and research-grade versus other grades cover the general distinction.
Reading a SNAP-8 listing critically
Three things on a research listing deserve a close look. First, the sequence should be stated and should match Ac-EEMQRRAD-NH2 with both terminal modifications, since an unacetylated or free-acid version is a different molecule with a different mass. Second, the identity line should report an observed mass near 1,075, and the purity chromatogram should not hide an oxidized shoulder; a methionine-containing peptide stored badly can pass a loose purity threshold while being partly sulfoxide. Third, claims about mechanism should be traceable to the SNAP-25 biology and the hexapeptide in vitro papers described above, not stated as established fact for the octapeptide. The aliquoting and oxidation guide explains how to handle methionine-containing peptides in solution so the material on the bench stays the material on the certificate.
Frequently Asked Questions
What is the difference between SNAP-8 and Argireline?
Argireline is acetyl hexapeptide-3, Ac-EEMQRR-NH2, six residues. SNAP-8 is acetyl octapeptide-3, Ac-EEMQRRAD-NH2, the same six residues plus alanine and aspartate at the C-terminus, with a molecular weight of 1,075.2. Both were designed by Lipotec from the N-terminal sequence of SNAP-25. The published in vitro mechanism work was done on the hexapeptide.
How is SNAP-8 supposed to work on the SNARE complex?
The hypothesis is that the peptide mimics the N-terminal region of SNAP-25 and competes with the native protein for its place in the forming syntaxin, SNAP-25 and synaptobrevin complex, destabilizing it and reducing vesicle fusion. Support comes from SNAP-25 truncation studies in purified protein and rat neuron systems and from Lipotec's in vitro release assays on the hexapeptide. Direct mechanistic data for the octapeptide are sparse in the peer-reviewed literature.
Is SNAP-8 an approved drug?
No. Acetyl octapeptide-3 is a cosmetic ingredient with an INCI name, not an approved drug in the United States or elsewhere. A research vial of the lyophilized peptide is neither a cosmetic product nor a drug; it is supplied for in vitro laboratory work.
Why does research-grade SNAP-8 come as a powder when cosmetic SNAP-8 is a liquid?
Cosmetic-grade material is sold as a dilute preserved aqueous solution designed to be dropped into an emulsion, so its documentation is a formulator's data sheet. Research-grade material is the lyophilized peptide with a lot-matched certificate stating identity, HPLC purity, net peptide content and endotoxin, which is what a laboratory needs to make a solution of known concentration.
Citations
- Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID 18498523
- Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160-163. PMID 8103915
- Fasshauer D, Margittai M. A transient N-terminal interaction of SNAP-25 and syntaxin nucleates SNARE assembly. J Biol Chem. 2004;279(9):7613-7621. PMID 14665625
- Yang Y, Xia Z, Liu Y. SNAP-25 functional domains in SNARE core complex assembly and glutamate release of cerebellar granule cells. J Biol Chem. 2000;275(38):29482-29487. PMID 10882724
- Hodel A. SNAP-25. Int J Biochem Cell Biol. 1998;30(10):1069-1073. PMID 9785471
- Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. PMID 27451932
- Kraeling ME, Zhou W, Wang P, Bruce Jenkins S, Bronaugh RL. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46-52. PMID 24754410
- Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025;44(2 Suppl):54S-63S. PMID 40673537
- PubChem. Acetyl octapeptide-3 (SNAP-8), CID 76283482. pubchem.ncbi.nlm.nih.gov
- Lipotec SA. Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides. European patent application EP1180524A1, priority 23 April 1999. patents.google.com
- Lubrizol Life Science. SNAP-8 peptide solution C, product page (INCI: aqua, acetyl octapeptide-3, caprylyl glycol). lubrizol.com
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- TH9507: The Stabilized GHRH Analog in the Research Literature
- Sermorelin (GHRH 1-29): What the Research Literature Covers
- Melanotan I and Melanotan II: Alpha-MSH Analogs in the Research Literature
- LL-37: The Human Cathelicidin Peptide in the Research Literature
- Ipamorelin: The Selective Ghrelin Receptor Agonist in the Research Literature
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
